- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03427619
OK432 (Picibanil) in the Treatment of Lymphatic Malformations
A Phase 2, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of OK-432 Immunotherapy in Individuals With Lymphatic Malformations
Standard of care for Lymphatic Malformations has been surgical excision. We have been using OK432/Picibanil (generously supplied by Chugai Pharmaceuticals in Japan) since 1992 with great success for macrocystic disease.
The objective of the study was to provide OK-432 immunotherapy to subjects with macrocystic or mixed (> 50% macrocystic) lymphatic malformations (LMs) and investigate the efficacy and safety of OK 432 as a treatment option in subjects with LMs.
Study Overview
Detailed Description
Lymphatic malformations are uncommon tumors that represent localized malformations in the development of the lymphatic system. They typically present in children under 2 years of age and in almost 50% of the cases, are diagnosed at birth. There is neither a racial nor a sexual tendency. The malformations can occur anywhere on the body, but typically they are in the head/neck area.
Morbidity can be significant. Besides the obvious cosmetic deformity caused by these tumors, there is risk of infection and airway compromise and even obstruction. However, effective therapeutic options are limited. Small lesions can be observed, although spontaneous resolution is unlikely. For larger lesions, surgery has been the traditional form of therapy. In the head and neck, in particular, lymphangiomas typically wrap themselves around major neurovascular structures, making total excision removal difficult, if not impossible, and thus the likelihood of recurrence is quite high. Because of these surgical limitations, alternate therapies have been considered; including cryotherapy, diathermy, and chemical sclerotherapy.
The investigators experience with using the drug for macrocystic disease(large cysts) since 1992 in the United States has been very promising compared to traditional surgery. Recurrence rate to date, has been very minimal as well. (<2%)
After the conclusion of the Phase 2 randomized study, all new subjects who presented with an LM and were eligible for treatment were treated under an open-label protocol for continued access to OK-432. This multicenter, open label study enrolled subjects between September 2005 and November 2017.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Rady Children's Hospital & Health Center San Diego
-
-
Colorado
-
Denver, Colorado, United States, 80218
- The Children's Hospital of Denver
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Saint Petersburg, Florida, United States, 33701
- All Children's Hospital
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Richard Smith, MD
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Spectrum Health-SHMG Ear, Nose, & Throat
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Children's Hospitals & Clinics of Minnesota - Minneapolis
-
-
New York
-
Syracuse, New York, United States, 13210
- SUNY Health Science Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Sciences University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- Children's ENT of Houston
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Children's Hospital of the Kings Daughter
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53279
- University of Wisconsin Hospital & Clinic
-
Milwaukee, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible to receive OK432 immunotherapy
- Patients must be ages 6 months to 17 years
- Patients must have a macrocystic Lymphatic Malformation
- Patients may have had surgical treatment for their Lymphatic Malformation
- Patients must have an imaging study to confirm the diagnosis of a macrocystic or mixed Lymphatic Malformation An MRI is preferred over a CT scan (an ultrasound may be used between injections if warranted, however an MRI or CT should be done pre and post treatment)
Exclusion Criteria:
- Penicillin allergy
- Women who are pregnant or nursing
- Patients who present with a temperature of 100.5 degrees F or greater
- Patients with mixed hemangioma-lymphangioma lesions
- Patients with a history OR a family history of rheumatic heart disease or post-streptococcal glomerulonephritis
- Patients with hemodynamic instability and respiratory failure
- Patients with a history OR a family history of obsessive-compulsive, tic disorders, or PANDA (pediatric autoimmune neuro-psychiatric disorder associated with streptococcal infections)
- Patients who demonstrate abnormalities in the history, physical examination or laboratory analysis which may indicate significant hepatic, hematologic, or renal disease
- Patients who are not in "good general health" (including patients with congenital disorders, chronic diseases, immunologic dysfunction, transplant recipients)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OK432 (Picibanil)
There is no control in this study.
All participants will receive the actual drug -OK432.
With each injection they may receive 0.01 to 0.05mg/mL 6-12 weeks apart up to 4 injections total.
|
OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging
Time Frame: 1 to 6 Months Post-Therapy
|
Clinical success was defined as having either a complete (90% 100%) or substantial (60% 89%) reduction in lymphatic malformation (LM) volume after treatment.
Response was determined using post treatment imaging studies at approximately 1 to 6 months after completion of treatment
|
1 to 6 Months Post-Therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Clinical Response 1 to 6 Months Post-Therapy as Assessed by Imaging
Time Frame: 1 to 6 Months Post-Therapy
|
Number of participants who demonstrated a complete (90%-100% reduction in LM volume), substantial (60%-89% reduction in LM volume), intermediate (20%-59% reduction in LM volume), or no (< 20% reduction in LM volume) response 1 to 6 months post-therapy as assessed by imaging
|
1 to 6 Months Post-Therapy
|
Number of Participants With Investigator-Evaluated Overall Response
Time Frame: 1 to 6 Months Post-Therapy
|
Investigator evaluated post-therapy clinical response based on physical exam and/or ultrasound was categorized as "Clinical Improvement" or "No Change" in the size of the cyst.
|
1 to 6 Months Post-Therapy
|
Change From Baseline in Lesion Volume
Time Frame: Baseline and 1 to 6 Months Post-Therapy
|
Percent change from baseline in lesion volume - pre-therapy to post therapy assessed by imaging.
|
Baseline and 1 to 6 Months Post-Therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard JH Smith, MD, University of Iowa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201107741
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphatic Malformations
-
University Hospital, ToursRecruitingLingual Microcystic Lymphatic MalformationsFrance
-
University Hospital, ToursUniversity Hospital, AngersRecruitingVascular Malformations | Lymphatic MalformationFrance
-
Palvella Therapeutics, Inc.RecruitingMicrocystic Lymphatic MalformationUnited States
-
University of ArkansasCompletedArteriovenous Malformations | Vascular Malformations | Lymphatic Malformations | Hemangiomas | Venous Malformations | Venular Malformations
-
Palvella Therapeutics, Inc.Not yet recruitingMicrocystic Lymphatic MalformationUnited States
-
University of ArkansasCompletedLymphatic Malformations | Hemangiomas | Venous Malformations
-
Sohag UniversityRecruitingVascular Malformations | Microcystic Lymphatic Malformation | Combined Vascular MalformationEgypt
-
Nanjing Children's HospitalRecruiting
-
Protara TherapeuticsRecruiting
-
Avalo Therapeutics, Inc.WithdrawnLymphatic MalformationUnited States
Clinical Trials on OK432
-
Carmel Medical CenterUnknown
-
University of IowaCompletedLymphatic MalformationsUnited States